ES2954151T3 - Compuesto para uso en métodos para el tratamiento de la poliquistosis renal - Google Patents

Compuesto para uso en métodos para el tratamiento de la poliquistosis renal Download PDF

Info

Publication number
ES2954151T3
ES2954151T3 ES16760627T ES16760627T ES2954151T3 ES 2954151 T3 ES2954151 T3 ES 2954151T3 ES 16760627 T ES16760627 T ES 16760627T ES 16760627 T ES16760627 T ES 16760627T ES 2954151 T3 ES2954151 T3 ES 2954151T3
Authority
ES
Spain
Prior art keywords
subject
mir
certain embodiments
kidney
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16760627T
Other languages
English (en)
Spanish (es)
Inventor
John R Androsavich
B Nelson Chau
Vishal Patel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regulus Therapeutics Inc
The University of Texas System
The University of Texas at Austin
Original Assignee
Regulus Therapeutics Inc
The University of Texas System
The University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regulus Therapeutics Inc, The University of Texas System, The University of Texas at Austin filed Critical Regulus Therapeutics Inc
Application granted granted Critical
Publication of ES2954151T3 publication Critical patent/ES2954151T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3525—MOE, methoxyethoxy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES16760627T 2015-08-26 2016-08-25 Compuesto para uso en métodos para el tratamiento de la poliquistosis renal Active ES2954151T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562210031P 2015-08-26 2015-08-26
PCT/US2016/048603 WO2017035319A1 (en) 2015-08-26 2016-08-25 Methods for treatment of polycystic kidney disease

Publications (1)

Publication Number Publication Date
ES2954151T3 true ES2954151T3 (es) 2023-11-20

Family

ID=56855838

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16760627T Active ES2954151T3 (es) 2015-08-26 2016-08-25 Compuesto para uso en métodos para el tratamiento de la poliquistosis renal

Country Status (14)

Country Link
US (3) US10633657B2 (enExample)
EP (2) EP4268891A3 (enExample)
JP (1) JP6929269B2 (enExample)
KR (2) KR20250049446A (enExample)
CN (2) CN114404440A (enExample)
AU (1) AU2016312590B2 (enExample)
CA (1) CA2995996A1 (enExample)
DK (1) DK3340993T5 (enExample)
ES (1) ES2954151T3 (enExample)
IL (1) IL257596B (enExample)
MA (1) MA44836A (enExample)
MX (1) MX2018002354A (enExample)
RU (1) RU2742300C2 (enExample)
WO (1) WO2017035319A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3548011B1 (en) * 2016-12-05 2023-06-14 Regulus Therapeutics Inc. Methods for treatment of polycystic kidney disease
TWI769197B (zh) * 2016-12-05 2022-07-01 美商雷格勒斯治療公司 用於治療多囊腎病之組成物
EP3841220A1 (en) 2018-08-23 2021-06-30 Roche Innovation Center Copenhagen A/S Microrna-134 biomarker
WO2023060237A1 (en) 2021-10-08 2023-04-13 Regulus Therapeutics Inc. Methods and compositions for treatment of polycystic kidney disease
WO2024026354A2 (en) * 2022-07-27 2024-02-01 The General Hospital Corporation Methods and compositions for use in treating autosomal recessive polycystic kidney disease (arpkd)
WO2024254639A1 (en) * 2023-06-16 2024-12-19 PYC Therapeutics Limited Compositions and methods for treatment of kidney disease
CN122295113A (zh) * 2023-11-22 2026-06-26 国立大学法人东海国立大学机构 囊性肾病的预防和/或治疗剂

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005013901A2 (en) * 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
RU2426532C2 (ru) 2004-03-17 2011-08-20 Новартис Аг Применение органических соединений
WO2007126150A1 (ja) * 2006-04-27 2007-11-08 National University Corporation Nagoya University 癌の新規治療用組成物
WO2008002971A2 (en) * 2006-06-29 2008-01-03 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CA3144493A1 (en) 2006-10-03 2008-04-10 Arbutus Biopharma Corporation Lipid containing formulations
US20090105174A1 (en) * 2007-04-20 2009-04-23 Amgen Inc. Nucleic acids hybridizable to micro rna and precursors thereof
WO2009143403A1 (en) * 2008-05-23 2009-11-26 Targacept, Inc. Combination therapy for the management hypertension
US20150299702A1 (en) * 2012-11-30 2015-10-22 Aarhus Universitet Circular rna for inhibition of microrna
EP3060217B1 (en) * 2013-10-24 2022-06-08 Mayo Foundation for Medical Education and Research Treatment of polycystic diseases with an hdac6 inhibitor
JP2017511694A (ja) * 2014-02-12 2017-04-27 トーマス・ジェファーソン・ユニバーシティ マイクロｒｎａ阻害剤を使用するための組成物および方法
EP3548011B1 (en) 2016-12-05 2023-06-14 Regulus Therapeutics Inc. Methods for treatment of polycystic kidney disease
TWI769197B (zh) 2016-12-05 2022-07-01 美商雷格勒斯治療公司 用於治療多囊腎病之組成物

Also Published As

Publication number Publication date
RU2018108206A (ru) 2019-09-27
NZ740040A (en) 2024-07-26
JP2018528945A (ja) 2018-10-04
KR20250049446A (ko) 2025-04-11
IL257596A (en) 2018-04-30
US11168325B2 (en) 2021-11-09
RU2018108206A3 (enExample) 2020-01-14
CA2995996A1 (en) 2017-03-02
IL257596B (en) 2022-08-01
AU2016312590B2 (en) 2021-12-02
US10633657B2 (en) 2020-04-28
WO2017035319A1 (en) 2017-03-02
KR20180080181A (ko) 2018-07-11
US20190153442A1 (en) 2019-05-23
EP4268891A2 (en) 2023-11-01
HK1256883A1 (en) 2019-10-04
AU2016312590A1 (en) 2018-03-15
DK3340993T5 (da) 2024-10-07
EP4268891A3 (en) 2024-01-24
EP3340993A1 (en) 2018-07-04
DK3340993T3 (da) 2023-08-21
EP3340993B1 (en) 2023-06-14
US20220025372A1 (en) 2022-01-27
MX2018002354A (es) 2018-12-10
WO2017035319A8 (en) 2021-03-11
JP6929269B2 (ja) 2021-09-01
CN114404440A (zh) 2022-04-29
US20200231971A1 (en) 2020-07-23
CN108135922A (zh) 2018-06-08
RU2742300C2 (ru) 2021-02-04
MA44836A (fr) 2018-07-04

Similar Documents

Publication Publication Date Title
US11168325B2 (en) Methods for treatment of polycystic kidney disease
KR102759999B1 (ko) 다낭성 신장 질환의 치료를 위한 변형된 올리고뉴클레오타이드
KR102780365B1 (ko) 다낭성 신장 질환의 치료 방법
HK40101442A (en) Compound for use in methods for treatment of polycystic kidney disease
HK40069750A (en) Methods for treatment of polycystic kidney disease
HK1256883B (en) Compound for use in methods for treatment of polycystic kidney disease
BR112019011164B1 (pt) Composto, oligonucleotídeo modificado e composição farmacêutica
HK40014087B (en) Methods for treatment of polycystic kidney disease
HK40014087A (en) Methods for treatment of polycystic kidney disease